logo
Plus   Neg
Share
Email

PNM Resources Narrows 2019 Ongoing Earnings Guidance - Quick Facts

PNM Resources (PNM) announced its management narrowed the 2019 consolidated ongoing earnings guidance to a range of $2.10 to $2.18 per diluted share to reflect colder New Mexico temperatures experienced throughout the first months of 2019.

For the fourth-quarter, ongoing EPS was $0.18 compared to $0.24, prior year. For fiscal 2018, ongoing EPS was $2.00 compared to $1.94.

"Fourth quarter earnings, while lower than the prior year, were strengthened by colder temperatures in New Mexico. These weather impacts, combined with the continued strength in load growth for both New Mexico and Texas, resulted in earnings just above our 2018 guidance range. As unprecedented demand for new service continues in our Texas service territory and the renewable energy potential in New Mexico comes to the forefront, we continue to revise our investment plans to reflect incremental growth opportunities," said Pat Vincent-Collawn, PNM Resources' CEO.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd. Avalon Furniture is recalling about 9,500 units of Cottage Town Bedroom Furniture collection sold through Rooms To Go due to violation of federal lead paint ban, the U.S. Consumer Product Safety Commission said in a statement. According to the agency, the base coat paint used on pieces within the furniture collection contains levels of lead that exceed the federal lead paint standard. Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints. In the trial, Kevzara was added to best supportive care compared to best supportive care alone (placebo). The companies have stopped the U.S. trial.
Follow RTT